Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral 5-ALA mediated flexible fluorescence cystoscopy in NMIBC
jRCTs031230643Recruiting
- Sponsor
- SBI Pharmaceuticals
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 5-aminolevulinic acid in non-muscle-invasive bladder cancer (NMIBC), sponsored by SBI Pharmaceuticals. Primary endpoint: Specificity in bladder neck and trigone. Started Mar 2024; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCTs031230643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230643.